N-Acetyl-Cysteine for Healing of Amputation Stumps in the Setting of Diabetes
Phase: EARLY_PHASE1
Conditions: Diabetes Mellitus, Critical Limb Ischemia, Lower Limb Amputation Knee, Peripheral Arterial Disease
Sponsor: Washington University School of Medicine

PROTOCOL DOCUMENT 
 
N-Acetyl-Cysteine for Healing of Amputation Stumps in the 
Setting of Diabetes 
 
 
Short Title:  NAC 
 
 
NCT03253328 
 
 
Protocol Version 11.0 
Date: March 26, 2020 
 
 

 
N-ACETYL-CYSTEINE FOR HEALING OF AMPUTATION 
STUMPS IN THE SETTING OF DIABETES 
 
 
 
 
 
 
 
Mohamed Zayed, MD PhD 
 
 
 
 
 
Protocol Version 11.0 
Date: March 26, 2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
TABLE OF CONTENTS 
 
A 
INTRODUCTION ................................................................................................................................. 5 
A1 
STUDY ABSTRACT ............................................................................................................................. 5 
A2 
PRIMARY HYPOTHESIS ...................................................................................................................... 5 
A3 
PURPOSE OF THE STUDY PROTOCOL .................................................................................................. 5 
B 
BACKGROUND ................................................................................................................................... 6 
B1 
PRIOR LITERATURE AND STUDIES ...................................................................................................... 6 
B2 
RATIONALE FOR THIS STUDY ............................................................................................................. 7 
C 
STUDY OBJECTIVES ......................................................................................................................... 7 
C1 
PRIMARY AIM 1 ................................................................................................................................. 7 
C2 
PRIMARY AIM 2 ................................................................................................................................. 7 
C3 
SECONDARY AIM ............................................................................................................................... 7 
C4 
RATIONALE FOR THE SELECTION OF OUTCOME MEASURES ............................................................... 7 
D 
INVESTIGATIONAL AGENT ........................................................................................................... 8 
D1 
PRECLINICAL DATA ........................................................................................................................... 8 
D2 
CLINICAL DATA TO DATE .................................................................................................................. 9 
D3 
DOSE RATIONALE AND RISK/BENEFITS ............................................................................................. 9 
E 
STUDY DESIGN ................................................................................................................................. 10 
E1 
OVERVIEW OR DESIGN SUMMARY ................................................................................................... 10 
E2 
SUBJECT SELECTION AND WITHDRAWAL ......................................................................................... 10 
2.a 
Inclusion Criteria ....................................................................................................................... 10 
2.a 
Exclusion Criteria ...................................................................................................................... 10 
2.b 
Ethical Considerations ............................................................................................................... 11 
2.c 
Subject Recruitment Plans and Consent Process ....................................................................... 11 
2.d 
Randomization Method and Blinding ......................................................................................... 12 
2.e 
Early Withdrawal of Subjects ..................................................................................................... 12 
2.f 
When and How to Withdraw Subjects ......................................................................................... 12 
2.g 
Data Collection and Follow-up for Withdrawn Subjects ........................................................... 12 
E3 
STUDY DRUG ................................................................................................................................... 12 
3.a 
Description ................................................................................................................................. 12 
3.b 
Treatment Regimen .................................................................................................................... 13 
3.c 
Preparation and Administration of Study Drug ......................................................................... 14 
3.d 
Subject Compliance Monitoring ................................................................................................. 14 
3.e 
Prior and Concomitant Therapy ................................................................................................ 14 
3.f 
Packaging ................................................................................................................................... 14 
3.g 
Blinding of Study Drug ............................................................................................................... 14 
3.h 
Receiving, Storage, Dispensing and Return ............................................................................... 14 
F 
STUDY PROCEDURES ..................................................................................................................... 15 
F1 
SCREENING FOR ELIGIBILITY ........................................................................................................... 15 
G 
SCHEDULE OF MEASUREMENTS ............................................................................................... 15 
A. 
NON-INVASIVE LASER ASSISTED FLUORESCENCE ANGIOGRAPHY (LAFA)...................................... 15 

G1 
VISIT 1............................................................................................................................................. 20 
G2 
SAFETY AND ADVERSE EVENTS ...................................................................................................... 20 
2.a 
Safety and Compliance Monitoring ............................................................................................ 20 
2.b 
Medical Monitoring ................................................................................................................... 20 
2.c 
Definitions of Adverse Events ..................................................................................................... 21 
2.d 
Classification of Events .............................................................................................................. 22 
i 
Relationship ............................................................................................................................................... 22 
ii 
Severity ..................................................................................................................................................... 22 
iii 
Expectedness ........................................................................................................................................... 22 
2.e 
Data Collection Procedures for Adverse Events ........................................................................ 23 
2.f 
Reporting Procedures ................................................................................................................. 23 
2.g 
Adverse Event Reporting Period ................................................................................................ 23 
2.h 
Post-study Adverse Event ........................................................................................................... 24 
G3 
STUDY OUTCOME MEASUREMENTS AND ASCERTAINMENT ............................................................. 24 
H 
STATISTICAL PLAN ........................................................................................................................ 24 
H1 
SAMPLE SIZE DETERMINATION AND POWER ................................................................................... 24 
H2 
INTERIM MONITORING AND EARLY STOPPING ................................................................................. 24 
H3 
ANALYSIS PLAN .............................................................................................................................. 24 
H4 
STATISTICAL METHODS ................................................................................................................... 24 
H5 
MISSING OUTCOME DATA ............................................................................................................... 25 
H6 
UNBLINDING PROCEDURES .............................................................................................................. 25 
I 
DATA HANDLING AND RECORD KEEPING............................................................................... 25 
I1 
CONFIDENTIALITY AND SECURITY .................................................................................................... 25 
I2 
TRAINING .......................................................................................................................................... 25 
I3 
CASE REPORT FORMS AND SOURCE DOCUMENTS ............................................................................. 26 
I4 
RECORDS RETENTION ....................................................................................................................... 26 
J 
STUDY MONITORING ..................................................................................................................... 26 
J1 
STUDY MONITORING PLAN ............................................................................................................... 26 
K 
STUDY ADMINISTRATION ........................................................................................................... 26 
K1 
ORGANIZATION AND PARTICIPATING CENTERS ............................................................................... 26 
K2 
FUNDING SOURCE AND CONFLICTS OF INTEREST ............................................................................ 26 
K3 
COMMITTEES ................................................................................................................................... 27 
K4 
SUBJECT STIPENDS OR PAYMENTS................................................................................................... 27 
K5 
STUDY TIMETABLE .......................................................................................................................... 27 
L 
PUBLICATION PLAN ....................................................................................................................... 27 
M 
ATTACHMENTS .............................................................................................................................. 27 
M1 
TABLES ........................................................................................................................................... 27 
M2 
INFORMED CONSENT DOCUMENTS................................................................................................... 27 
M3 
PATIENT EDUCATION BROCHURES................................................................................................... 27 
M4 
SPECIAL PROCEDURES PROTOCOLS ................................................................................................. 27 
M5 
QUESTIONNAIRES OR SURVEYS ....................................................................................................... 27 
N 
REFERENCES .................................................................................................................................... 28 
 
 
 

Introduction 
 
Study Abstract 
Approximately 2.5 million Americans currently have advanced critical limb ischemia (CLI) [1]. 
Patients with diabetes are at increased risk of advanced CLI and resultant complications such as 
wounds, gangrene, and severe infection.  This leads to more than 130,000 extremity amputations 
in the United States per year [2]. Poor major amputation site healing in patients with CLI and 
diabetes is associated with surgical site necrosis, dehiscence, and infection. In 40% of these 
patients, subsequent limb re-amputation or surgical site revision is required with added significant 
patient morbidity, extended disability, and increased healthcare costs [2, 3]. 
N-Acetyl-Cysteine (NAC) is a well-known thiol precursor of reduced glutathione [4, 5] and has 
been in clinical use for over 40 years.  It is Food and Drug Administration (FDA) approved as a 
mucolytic agent.  However its current primary clinical use is the treatment of acetaminophen 
poisoning – which is potentially life saving [6, 7]. Multiple studies and clinical trials have 
investigated the use of NAC as an antioxidant given its free thiol group and its ability to restore 
glutathione levels [8-10].   
 
Recent studies have demonstrated that NAC can blunt tissue oxidative stress and decrease 
insulin resistance [11, 12]. Preclinical studies in our laboratory have also demonstrated that NAC 
can augment tissue perfusion and arterial collateral maturation (arteriogenesis) in a novel murine 
hind limb ischemia – amputation model, as well as alter the phospholipid profile in vascular 
endothelial cells. Recent clinical trials have repeatedly demonstrated the safe administration of 
NAC [8-10].  We therefore hypothesize that perioperative administration of NAC in patients 
with CLI, with and without diabetes, who are undergoing major lower extremity amputation 
will improve tissue stump perfusion and alter tissue lipidomics. 
Primary Hypothesis 
Our primary hypothesis is that perioperative administration of NAC in patients with CLI, plus or 
minus diabetes, who are undergoing major lower extremity amputation will improve tissue stump 
perfusion and alter tissue lipidomics, ultimately reducing amputation associated morbidity with 
respect to wound breakdown, wound infection, and amputation revision. 
Purpose of the Study Protocol 
The purpose of this study protocol is to evaluate the safety and potential efficacy of NAC in the 
setting of peripheral arterial disease as a tissue augmentation agent in patients with CLI 
undergoing lower limb amputation.  This will be a Pilot Clinical trial designed to facilitate a future 
power calculation for a larger, likely multicenter trial that can evaluate the potential clinical benefit 
of using NAC to improve healing and perfusion of amputation stumps in diabetic patients. 
 
This study is highly innovative in that it will: i) explore a compelling new modality of therapy in a 
highly vulnerable, but frequently under-represented clinical trial patient population, and ii) 
represent the potential use of a low-cost, generic, well-established, and generally very safe 
pharmacological agent for an important clinical problem. This would otherwise not be pursued by 
drug pharmaceutical manufacturers due to anticipated low-profit margins from a generic 
pharmacological agent.  

Background 
 
Prior Literature and Studies 
Diabetes and CLI: Nearly 30 million Americans suffer from diabetes – a chronic metabolic 
disorder characterized by inappropriate hyperglycemia and increased risk of cardiovascular 
disease [13]. Diabetes is associated with altered serum lipidomics, endothelial cell dysfunction, 
and impaired arterial collateral formation [13]. These pathophysiologies make diabetic patients 
particularly prone to developing a distinct pattern of diffuse and recalcitrant peripheral arterial 
disease that leads to advanced CLI. Chronic inadequate supply of oxygen and nutrients to the 
extremity of these patients can lead to end-stage complications like non-healing wounds, 
infection, and gangrene [14]. Despite recent advances in the treatment and management of 
diabetic patients, CLI remains highly prevalent in this patient population, and results in high rates 
of major extremity amputations. Even when major extremity amputations are performed, healing 
at the surgical site in patients with diabetes is impaired due to poor blood flow at the arterial cul-
de-sac in the newly created amputation stump [15]. At the present time, there are no widely 
accepted treatment strategies to augment tissue perfusion in ischemic peripheral tissue 
 
NAC, Angiogenesis, and Tissue Perfusion:  First FDA-approved as a pulmonary mucolytic 
agent in the 1970s, NAC was later found to be an effective treatment for acetaminophen poisoning 
by restoring hepatic glutathione levels [6]. Recent studies demonstrate that exogenous 
administration of NAC can increase the total antioxidant capacity of the intra- and extra-cellular 
milieu in both murine models as well as human subjects [16].  In streptozotocin (STZ)-treated 
rodents, NAC scavenger-of-free-radical properties are found to induce PI3K/AKT signaling in 
cardiomyocytes, reduce cardiac ischemia-reperfusion injury, and increases ischemic hind limb 
tissue angiogenesis and perfusion [17].  Consistent with these findings, we have also observed 
improved amputation stump perfusion and healing in a novel preclinical murine hind limb 
ischemia-amputation model. We also observed increased AKT phosphorylation in ECs following 
NAC treatment. In addition to the well-characterized antioxidant properties of NAC, another 
proposed mechanism leading to the therapeutic benefits of NAC is inhibition of sarcolemmal 
phospholipid breakdown and therefore maintenance of cell membrane integrity [18].  Therefore, 
these studies support the role of NAC in augmenting compensatory tissue perfusion in the setting 
of ischemia, and raise the possibility that this beneficial effect of NAC may be related to altered 
tissue phospholipid content 
 
NAC in CLI and Diabetes: Recent studies exploring the therapeutic benefits of NAC in the setting 
of CLI and diabetes, demonstrated that it can preserve insulin content, induce insulin gene 
expression, improve insulin sensitivity, and restore beta islet cell morphology and function [11, 
12, 18].  The molecular mechanisms by which these effects occur are not yet understood, but it 
is proposed that NAC therapeutic benefits in the setting of diabetes may be a result of altering 
cellular lipid metabolism.  Accordingly, NAC treatment was recently found to decrease serum free 
fatty acids, increase serum HDL, and alter the expression profile of specific cellular 
phosphatidylinositols that are known to be essential for normal glucose metabolism [19, 20]. 
Consistent with this notion, we recently observed that NAC not only affects the levels of key 
phospholipid synthesis enzymes such as choline-ethanolamine phosphotransferase 1 (CEPT1; 
which 
regulates 
the 
synthesis 
of 
the 
majority 
of 
phosphatidylcholines 
and 
phosphatidylethanolamines), but can also alter the phospholipid ratios (PC:PE, a marker of ER 
stress) in endothelial cells.  This body of evidence supports the potential important functions that 

NAC plays in the setting of CLI as well as potentially diabetes as well, and points to previously 
unknown effects of NAC on key phospholipid synthesis pathways. 
 
Rationale for this Study 
Aside from smoking cessation and physical exercise, there are currently no known effective 
medical treatments for patients with advanced non-surgically correctable CLI [13, 21].  In addition, 
the prevalence of amputations resulting from CLI among diabetic patients is disturbingly high [2].  
Based on our recent preclinical studies, we are proposing a pilot clinical trial to further explore the 
potential therapeutic benefits of NAC in healing extremity amputation stumps in the setting of CLI, 
plus or minus diabetes. These studies are highly innovative in that they: i) explore a compelling 
new modality of therapy in a highly vulnerable, but frequently under-represented clinical trial 
patient population, ii) explore a completely novel and not previously reported NAC mechanism of 
action on phospholipid synthesis and expression, and iii) represent the potential use of a low-cost, 
generic pharmacological agent, which would otherwise not be pursued by drug pharmaceutical 
manufacturers due to low-profit margins. In short, this proposal may establish a conceptual 
infrastructure for future larger clinical trials exploring the use of NAC in patients with CLI and with 
and without diabetes, and identify a previously unknown novel mechanism of action for NAC. 
We believe that previous literature supporting the role of NAC in augmenting compensatory tissue 
perfusion raises the possibility that this may be an advantageous therapeutic agent to favorably 
alter the tissue lipidomic profile of diabetic patients receiving NAC. We believe that NAC offers a 
new treatment strategy for patients with CLI undergoing lower extremity amputation with the intent 
to improve tissue perfusion, healing, and reduce morbidity and mortality associated with lower 
limb amputation. 
 
Study Objectives 
 
Primary Aim 1 
Determine whether NAC can affect major lower extremity amputation stump perfusion by 
POD (Post-operative Day) 5 
Primary Aim 2 
Determine whether NAC can affect major lower extremity stump healing for 30 days 
following amputation.  
Secondary Aim  
Determine the effect size in diabetic patients that is necessary to power a larger clinical 
trial to determine whether NAC treatment can improve tissue perfusion and healing at 
major lower extremity amputation stumps. 
 
Rationale for the Selection of Outcome Measures 
In this pilot clinical study we propose to conduct a prospective, randomized, double-blinded, 
placebo-controlled clinical trial for 30 days for patients with CLI who undergo a major (above-knee 
or below-knee) lower extremity amputation. By exploring the primary endpoints we aim to 

determine whether NAC can affect amputation stump perfusion and healing.  Based on our 
preclinical data, we hypothesize that NAC will augment both amputation stump perfusion as well 
as healing.  We will utilize the data from this trial to determine the true effect size that is necessary 
for a larger clinical trial to determine the clinical efficacy of NAC is healing surgical sites such as 
major lower extremity amputation stumps. 
In addition, we will obtain MR perfusion studies on 6 subjects (3 NAC and 3 placebo) conducted 
at approximately post-operative day (POD) 4.  The study team will continue to remain blinded to 
their study drug randomization. The study pharmacist will notify the study team of which 
subjects will be eligible to have an MR perfusion study. For example, if the MR perfusion portion 
of the study has already recruited 3 patients from the NAC group, and the forth eligible patient 
also randomizes to NAC, the pharmacy will notify the study team that the patient is not eligible 
for the MR perfusion study.   
 
   
 
MR perfusion studies will be performed by Dr. Jie Zheng and his research on a Siemens Prisma 
3.0 T MR (Software version VE11c (latest software version), 40 mT/meter; 200 μsec rise time) 
in CCIR. The subject will lie down on a MRI table and The MRI scan will undergo only at rest. 
The MR study will be performed without using of any MR contrast media. The scan protocol will 
involve scout imaging to localize the calf and stump regions. This will be followed by perfusion, 
diffusion, and oxygenation imaging in these regions. The expected scan time will be less than 
45 min. 
 
  
 
MR perfusion studies will only be used for research purposes (i.e. will not direct medical/clinical 
therapy). MR perfusion will be used to assess skeletal muscle perfusion at the healing 
amputation stump. This data will be used in adjunct to assess overall stump perfusion along 
with the LAFA studies that are will already be performed on the patient.  
 
Investigational Agent  
 
Preclinical Data 
Further studies exploring the therapeutic benefits of NAC in the setting of diabetes, demonstrated 
it can preserve insulin content, induce insulin gene expression, improve insulin sensitivity, and 
restore beta islet cell morphology and function [11, 12, 18].  The molecular mechanisms by which 
these effects occur are not yet understood, but it is proposed that NAC therapeutic benefits in the 
setting of diabetes may be a result of altering cellular lipid metabolism.  Accordingly, NAC 
treatment was recently found to decrease serum free fatty acids, increase serum HDL, and alter 
the expression profile of specific cellular phosphatidylinositols that are known to be essential for 
normal glucose metabolism [19, 20]. Consistent with this notion, we recently observed that NAC 
not only affects the levels of key phospholipid synthesis enzymes such as choline-ethanolamine 
phosphotransferase 1 (CEPT1; which regulates the synthesis of the majority of 
phosphatidylcholines and phosphatidylethanolamines), but can also alter the phospholipid ratios 
(PC:PE, a marker of ER stress) in endothelial cells.   
 

We recently performed a preclinical study to explore the effect of NAC in healing amputation 
stumps in the setting of diabetes. C57B6 adult mice with streptozotocin-induced diabetes 
underwent unilateral hindlimb femoral artery ligation, followed by a staged infrageniculate 
amputation of the malperfused limb one week after induction of ischemia. Compared to controls, 
mice treated with daily NAC demonstrated improved stump healing, increased hindlimb stump 
perfusion post-amputation, increased hindlimb adductor muscle neovascularization, and 
decreased adductor muscle fiber damage. NAC treatment stimulated EC migration and 
proliferation in a phospholipase C β (PLC β)-dependent fashion, and decreased Gαq 
palmitoylation. In vivo, NAC treatment also decreased Gαq palmitoylation in ischemic and non-
ischemic hindlimbs, as well as in hindlimbs of acyl protein thioesterase-1 knockout mice with 
impaired palmitoylation dynamics.  These findings are currently pending publication in a peer-
reviewed scientific journal. 
 
Clinical Data to Date  
Currently, there is no clinical data examining the utility of NAC with regards to improving tissue 
stump vascular perfusion and altering lipidomic profiles in diabetic patients.  Other clinical trials 
that previously explored the clinical efficacy of NAC, demonstrated that NAC was well tolerated 
by study patients. 
 
Dose Rationale and Risk/Benefits  
 
A variety of dosing regiments are well studied for the clinical use of NAC.  The majority of these 
are using oral formulation.  The most commonly studied oral dose is 600mg twice daily, though 
other studies evaluating 1200mg vs 600mg did show slightly better outcomes with the higher dose 
[22] for patients at risk of contrast nephropathy.   Patient’s requiring emergent coronary 
angiography or procedures, have received NAC safely.   
 
For this study, we will administer NAC 1200mg twice-daily, intravenously. 
 
Risks of NAC include rare side effects or adverse reactions.  Severity of side effects are described 
as moderate, and include wheezing, tightness in the chest, or difficulty breathing, though the most 
commonly reported adverse effects for IV formulations include rash, urticaria, and pruritus. Other 
side effects of the oral formulation include nausea, vomiting, diarrhea, or constipation.  Patients 
with asthma are at higher risk of developing bronchospasm with inhaled NAC.  Patients with 
severe clinical asthma or end-stage liver disease will not be recruited to this study. 
 
NAC has deemed to be LIKELY SAFE in women (Pregnancy Category B) who are pregnant and 
breast-feeding, though it does cross the placenta; however, there is currently no literature 
demonstrating teratogenicity to a fetus. Patients who are pregnant or are infant nursing will not 
be eligible to participate in the study.  
 
 
Risks associated with MRI scan: 
 
Likely: During the MR imaging study, the subject may experience a loud pounding noise 
coming from the scanner. 
 

Less likely: The subject may experience some discomfort related to lying still in the scanner 
during the examination period (< 1 h). The subject may feel claustrophobic (anxious in small 
spaces) while lying in the MRI scanner. Typically, less than 5% of the subjects who have MRI 
exams feel claustrophobic. Should this occur, the subject will be allowed to get out of the scanner. 
Because of the powerful, high speed gradients in the MR system, some subjects (2-4%) 
experience slight tingling or tapping sensations in the arms and legs (mild peripheral 
neuromuscular stimulation). Tingling or tapping sensations stop when the machine is not 
scanning. 
 
 
Study Design  
 
Overview or Design Summary 
In this pilot clinical study we propose to conduct a prospective, randomized, double-blinded, 
placebo-controlled clinical trial, in 50 human subjects with CLI who have undergone a major 
(above-knee or below-knee) lower extremity amputation. 25 patients will receive NAC 1200mg 
intravenously twice a day for 6 consecutive days following amputation.  25 patients will receive 
placebo saline intravenous infusion twice a day for 6 days following amputation.  Post-amputation 
patients will be monitored for specific anthropometric parameters and stump perfusion 
assessments (using laser-assisted fluorescent angiography and transcutaneous oxygen pressure 
measurement). The primary study endpoints are to determine if lower extremity stump 
healing and perfusion are affected by perioperative NAC administration.  A secondary 
endpoint will be to determine the effect size that would be necessary to power a larger 
clinical trial to determine whether NAC treatment can affect tissue perfusion and healing 
at major lower extremity amputation stumps in patients with CLI. 
 
Subject Selection and Withdrawal  
 
Inclusion Criteria  
Inclusion criteria for recruited subjects will be as follows: 
• 
Subject undergoing elective major (above-knee or below-knee) lower extremity 
amputation for CLI 
• 
Both male and female patients 
• 
All ethnic groups 
• 
Between of the ages of 30-90 years old 
1.a 
Exclusion Criteria  
Exclusion criteria for patients will be as follows: 
• 
Pregnant women, and women who are breastfeeding 
• 
Known history of end-stage liver disease 
• 
Severe asthma 
• 
Heavy alcohol consumption (male > 2 drinks per day and women > 1 drink per day) 
• 
Individuals actively receiving chemotherapy. 

• 
Anticipated enrollment in another study that investigates another drug agent within 30 
days from enrollment in this study.  
• 
Patients receiving carbamazepine. 
• 
Severe anemia (HCT < 22). 
• 
Allergy to either NAC or ICG 
 
All inclusion and exclusion criteria will be verified from patient chart in Epic and through self report 
and.or LAR report; in particular, alcohol consumption and participation in another drug research 
study to obtain the most current information.  Email correspondence between RC, PI, and other 
study team members regarding patient enrollment may be included in the subjects chart to serve 
as a real time documentation of PI’s approval to enroll participant, in addition to signature in CRFs. 
Ethical Considerations  
Ethical considerations for this particular clinical study include the issue of beneficence, non-
maleficence, patient autonomy and the voluntary, competent decision making of the individual 
patients participating in this clinical trial [23].  For this reason, we believe that the following 
requirements will be satisfied for each patient enrolled in the clinical trial: 
• 
Physical and psychological risks to subjects are minimized. 
• 
Physical and psychological risks to subjects are reasonable in relation to anticipated 
benefits to those subjects and to the importance of the general knowledge that may 
reasonably be expected to result. 
• 
Selection of subjects is equitable 
• 
Informed consent will be obtained, including at least the following items being 
communicated to potential participants or their authorized surrogates: 
• 
Purposes of the research, its expected duration, and the nature of any 
interventions/experiments; 
• 
Anticipated risks and benefits of participation and the reasonable alternatives to 
participation in the research protocol; 
• 
Confidentiality provisions relating to the research records; 
• 
Any compensation and/or treatment available for research related injuries; 
• 
The right to not participate and to discontinue participation at any time without 
penalty. 
• 
Informed consent will be documented appropriately. 
 
Subject Recruitment Plans and Consent Process 
Subjects that meet study inclusion and exclusion criteria, who are undergoing an elective above-
knee or below-knee amputation at the Washington University School of Medicine-affiliated 
Barnes-Jewish Hospital (BJH), will be approached for participation in this pilot clinical trial.  
Potential subjects will be identified by reviewing the weekly operative schedule and via referral 
from vascular surgery faculty study co-investigators.   
 

Prior to the scheduled operation, the study investigator will screen eligible patients by reviewing 
the medical chart. Patients that meet study inclusion and exclusion criteria will be approached for 
informed consent. Informed consent will be obtained by a member of the vascular surgery 
research team in accordance with institutional regulations, prior to any further actions in the study. 
Per standard clinical procedures, all patients will also be evaluated by preoperative anesthesia 
services. 
Randomization Method and Blinding 
Upon consent and enrollment in the study, relevant subject information will be relayed to the 
Barnes Jewish Hospital (BJH) Investigational Pharmacy.  Prior to proceeding to the operating 
room for lower extremity amputation, the patients will be randomized 1:1 by the BJH 
Investigational Pharmacy to either placebo saline infusion (twice daily) or a standard adult 
intravenous dose of NAC (1200mg twice daily) for 6 days post-amputation during the usual post-
operative inpatient extremity off-loading and stump monitoring period. The pharmacy will maintain 
blinding, with no member of the investigational team having access to the record until the 
conclusion of the trial.  
Early Withdrawal of Subjects  
Patients unable to tolerate the administration of the drug will be withdrawn from the study at any 
point during their hospitalization and will continue to be monitored until their condition stabilizes.  
Patients unable to participate in the Post-operative Day 0 Non-invasive Laser Assisted 
Fluorescence Angiography (LAFA) will be withdrawn from the study at that time point and will not 
receive the investigational product.  Subjects for which continuous IV access is not medically 
indicated during the 6 day study drug administration period may be withdrawn from the study. 
Patients unable to participate in follow-up appointments will also be withdrawn from the study. 
When and How to Withdraw Subjects  
Patients unable to tolerate the administration of the drug will be withdrawn from the study trial at 
any point during their hospitalization.  Patients unable to participate in follow-up appointments will 
also be withdrawn from the study. They will continue to be monitored for adverse events as 
inpatients for the duration of their hospitalization. Patients unable to participate in the Post-
operative Day 0 Non-invasive Laser Assisted Fluorescence Angiography (LAFA) will be 
withdrawn from the study at that time point and will not receive the investigational product. No 
further study follow up will be required. 
 
Data Collection and Follow-up for Withdrawn Subjects  
Patient data will be collected up until time of withdrawal from the study and pooled into the 
collective analysis along with all other patients. 
 
Study Drug  
Description  
N-acetyl cysteine (NAC) ((2R)-2-acetamido-3sulfanylpropanoic acid) is an amino acid derivative 
of L-cysteine, which is a precursor to glutathione and cysteine.  Historically, NAC has been used 
to treat acetaminophen overdose [6], as well as mucous secretions in patients with cystic fibrosis 
or chronic obstructive pulmonary disease [24]. 
 

Pharmacokinetics including the following [24] : 
 
Distribution: The steady-state volume of distribution (Vdss) and the protein binding for 
acetylcysteine were reported to be 0.47 liter/kg and 83%, respectively.  
 
Metabolism: N-acetyl-cysteine may form cysteine, disulfides, and conjugates in vivo (N, 
N’-diacetylcysteine, N-acetyl cysteine-cysteine, N-acetyl cysteine-glutathione, N-acetyl 
cysteine-protein, etc). Based on published data, it was reported that after an oral dose of 
35S-acetylcysteine, about 22% of total radioactivity was excreted in urine after 24 hours. 
No metabolites were identified.  
 
Elimination: After a single intravenous dose of N-acetyl cysteine, the plasma concentration 
of total N-acetyl cysteine declined in a poly-exponential decay manner with a mean 
terminal half-life (T1/2) of 5.6 hours. The mean clearance (CL) for N-acetyl cysteine was 
reported to be 0.11 liter/hr/kg and renal CL constituted about 30% of total CL.  
 
Treatment Regimen  
Upon study enrollment, patients will be randomized 1:1 by BJH Investigational Pharmacy to either 
placebo ½ normal saline infusion (twice a day) or a standard adult intravenous dose of NAC 
(1200mg twice a day) for 6 days post-amputation. The BJH Investigational Pharmacy will perform 
this with knowledge of the patient’s medical record number (MRN), and without knowledge of any 
pre-existing medical conditions, comorbidities, past medical history, prior interventions, etc. The 
first infusion will be administered within three hours from leaving the operating room. The second 
infusion will be a minimum of 6 hours after the first infusion, or at 21:00 in an attempt to be 
consistent with routine hospital BID dosing times.  Patients will receive their scheduled infusions 
as long as they are hospitalized according to the chart below (Table 1). If medication is not 
administered within that window, dose will not be given to not interfere with the rest of the doses. 
 
 
Table 1: 
Post-operative Day (POD) 
Infusion Schedule 
POD 0 
1. Within 3 hours from the conclusion 
of the operation 
2. Approximately 6 hours after first 
infusion, or at 21:00 +/- 6 hours 
POD 1 
1. 9:00 +/- 6 hours 
2. 21:00 +/- 6 hours 
POD 2 
1. 9:00 +/- 6 hours 
2. 21:00 +/- 6 hours 
POD 3 
1. 9:00 +/- 6 hours 
2. 21:00 +/- 6 hours 
POD 4 
1. 9:00 +/- 6 hours 

2. 21:00 +/- 6 hours 
POD 5 
1. 9:00 +/- 6 hours 
2. Anticipated 
discharge, 
second 
infusion may be given if patient is 
still inpatient or missed any doses 
 
Preparation and Administration of Study Drug  
All investigational doses will be prepared by the research pharmacy and prepared in a manner 
that both active and placebo doses appear identical to protect the blind. Preparation of each dose 
will be performed using aseptic technique, and within a laminar flow hood. Each dose will be a 
total volume of 50 mL and will be administered over a period of 30 minutes through an IV. N-
acetyl-cysteine will not be infused in the same intravenous line as iron-products, cefepime, or 
ceftazidime. 
Subject Compliance Monitoring  
The Barnes-Jewish Hospital inpatient electronic medication administration record (eMAR) will be 
used to assess compliance; significant patient noncompliance, defined as refusal or inability to 
adhere to the protocol requirements, will lead to subject withdrawal. 
Prior and Concomitant Therapy  
Use of any investigational agent within 30 days before the first dose of study drug and until after 
the last evaluation will not be allowed.  Since concomitant use of N-acetyl-cysteine and 
carbamazepine may cause decrease carbamazepine plasma concentrations resulting in an 
increased risk of seizures, patients who are receiving carbamazepine will not be enrolled in the 
study. 
 
Concurrent use of N-acetyl-cysteine and nitroglycerin may result in enhanced hypotension and 
nitroglycerin-induced headache.  Therefore patients who receive both agents will be monitored 
by members of the study team for any potential anticipated complications.  
 
All other concomitant medications that are necessary for the health and well-being of the patient 
that are not specifically prohibited by the protocol are permitted. 
Packaging  
Acetadote (acetyl-cysteine) Injection is available as a 20% solution (200mg/mL) in 30 mL single 
dose glass vials. Acetadote is sterile and can be used for I.V. administration. 
Blinding of Study Drug  
All intravenous doses will be prepared in identical evacuated IV containers with a total volume of 
50mL. N-acetyl cysteine is a clear and colorless solution, and no additional blinding material will 
be required. 
 
Receiving, Storage, Dispensing and Return  
Medications will be prepared by the research pharmacy and delivered to the treating nurse; study 
drug will be blinded to the research team and the study participant. The research pharmacy will 

maintain documentation of medication procurement and preparation, as well as randomization, 
dispensing, and accountability logs. All medications will be stored in a secure location within the 
research pharmacy and maintained under controlled environmental conditions. Unused doses will 
be returned to the research pharmacy, whereas used or unwanted partially infused doses will be 
destroyed on the nursing unit per policy. 
Study Procedures  
 
Screening for Eligibility 
 
As discussed in 2.c, subjects that meet study inclusion and exclusion criteria, who are undergoing 
an elective above-knee or below-knee amputation at the Washington University School of 
Medicine-affiliated BJH, will be included in this pilot clinical trial.  
 
Potential subjects will be screened by reviewing the weekly operative schedule, and via referral 
from vascular surgery faculty study co-investigators.  Prior to the scheduled operation, eligible 
patients will be approached for informed consent. Informed consent will be obtained by a member 
of the vascular surgery research team in accordance with institutional regulations, prior to any 
further actions in the study. After informed consent is obtained, a baseline clinical evaluation will 
be performed including lower extremity anthropometric evaluation, medical history and vital signs 
documentation. Per standard clinical procedures, all patients will also be evaluated by 
preoperative anesthesia services. Subjects may participate in the study a second time on 
ipsilateral or contralateral site if all Inclusion /Exclusion is reviewed and verified prior to second 
surgery.  Patient records from an outside hospital or facility may be obtained and used for 
screening and/or follow up in patient care. 
 
Schedule of Measurements 
A. 
Non-invasive Laser Assisted Fluorescence Angiography (LAFA) 
 
Location of Procedure:  
- 
Barnes-Jewish Hospital Operating Rooms 
- 
4400/8300/7400/7500 Inpatient Hospital Units 
- 
Other Hospital Units also housing vascular surgery patients  
 
Time of Data Collection:  
- 
Postoperative Day 0:  Obtained in the operating room after amputation, but before 
placement of dressings. 
- 
Postoperative Day3:  Obtained following dressing removal at bedside in the inpatient 
hospital unit. 
- 
Postoperative Day5: Obtained at the bedside in the inpatient hospital unless the 
patient is discharged. 
 
Contraindications to LAFA: 
- 
Patient refusal/inability to precipitate in measurement before or during data collection. 

- 
Allergic reaction previously documented to Indocyanine green (ICG) fluorescent dye 
(a contraindication to LAFA does not exclude the patient from other measurements 
within the study protocol). 
- 
Patient unable to lie supine and immobile for at least 10 minutes during the imaging 
procedure. 
- 
End-stage liver disease 
- 
Severe clinical asthma 
 
LAFA Procedural Steps: 
1. Each patient is entered into the Novadaq SPY Elite® computer system, with pre-set 
optimized settings for appropriate visualization for LAFA. 
2. Utilizing a standard protocol per the manufacturer (Novadaq SPY Elite® system), a 
7.5mg (3mL) solution of ICG (reconstituted with sterile saline) is injected intravenously 
into each patient.  
3. The patient is asked to lie supine, immobile for a period of approximately 10 minutes 
4. The device is placed over the limb/amputation stump being studied and centered to 
allow full visualization of the entire stump 
a. Prop up and immobilize stump 
b. Obtain a still color image of the stump 
c. Start an image buffering time of between 10-30 seconds 
d. ICG is intravenously injected by the patient’s nurse or a member of the study 
team. 
e. ICG injection is followed by a 10mL of sterile saline flush in the same 
intravenous line. 
f. A member of the study team will obtain LAFA imaging of the stump for a total of 
150-180 seconds. 
g. All study images will be stored on the Novadaq SPY Elite® system hard drive. 
Study images, including only the study ID and date of exam, will be loaded onto 
a jump drive and then immediately downloaded onto the WUSTL Department 
of Surgery/Vascular network drive. The images will then be deleted from the 
jump drive.. 
5. Each study patient will be carefully monitored by a physician, nurse practitioner, 
physician assistant or nurse for signs and symptoms of allergic reaction or intolerance 
to this non-invasive procedure until discharge. 
 
B. 
Measurement of Transcutaneous Oxygen Pressure (TcPO2) 
 
Location of Procedure: 
- 
Barnes-Jewish Hospital Operating Rooms 
- 
4400/8300/7400/7500 Inpatient Hospital Units 
- 
Other Hospital Units also housing vascular surgery patients  
 
Time of Data Collection:  
- 
Day 0 (Day of Operation):  If possible and/or equipment available, obtained prior to 
the operation at the anticipated level of the amputation. 
- 
Postoperative Day3:  If possible and/or equipment available, obtained following 
dressing removal at bedside in the inpatient hospital unit. 
- 
Postoperative Day5:  If possible and/or equipment available, also obtained at bedside 
in the inpatient hospital unit if the patient is still in-house. 
 

Contraindications to Measurement: 
- 
Patient refusal/inability to participate in measurement before or during data collection 
- 
Patient SpO2 < 92%, Patient is febrile >38˚C, unstable vitals 
- 
Patient unable to lie supine for at least 20 minutes during measurement collection 
- 
Patient unable to breathe normobaric oxygen 
- 
*A contraindication to TcPO2 measurements does not exclude the patient from other 
measurements within the study protocol 
 
Protocol Steps: 
1. Ensure patient meets the eligibility criteria 
listed 
above. 
2. Keep patient covered, and expose the 
anticipated 
amputation 
site 
or 
at 
the 
amputation stump. Do not elevate the site 
throughout the measurement collection.  
3. Select 4 collection sites as follows: 
1. 3 sites on the anticipated amputation site 
or at 
the stump site, one per section. (Figure 1) 
2. 1 control site on the left anterior chest in 
area 
indicated on figure. (Figure 1) 
4. Electrodes will be placed as per TCM Manual 
instructions, replicated below with the following 
specifications: 
1.  Temp. set to 45˚C. 
2.  Do not place probes on scar tissue or 
dermatologically compromised sites. 
3.  Do not place probe over bone. 
5. After 15-20 minutes, record the TcPO2 numbers in all 4 sites. Mark the location of the sites for 
future measurements to ensure a consistent location for measurement and control (days 2 
and 4). 
6. Remove probes from patients. 
 
 
Data Analysis: 
After TcPO2 measurements have been collected, the 3 amputation site measurements will be 
averaged to calculate a mean TcPO2. The control site measurement on the operated leg will be 
used to calculate a Regional perfusion index (Mean TcPO2 / Chest/Control TcPO2). The non-
operated leg measurement site (compared against the operated site) will be used to determine if 
lower TcPO2 values in the amputation site are due to regional or systemic oxygenation. 
 
 

C. 
Anthropometric Measurements 
 
Location of Procedure:  
- 
Barnes-Jewish Hospital Operating Rooms 
- 
Inpatient Hospital Units 
- 
Other Hospital Units also housing vascular surgery patients  
 
Measurements: 
Measurements will be collected as long as the patient is hospitalized, including: 
1. Temperature (daily maximum and minimum) 
2. Blood Pressure Range 

3. Heart Rate Range 
4. SpO2 Range 
5. Respiratory Rate Range 
6. Amputation wound assessment on POD 3 (if stump dressings are off and still hospitalized) 
and POD 5 (if stump dressings are off and still hospitalized). 
 
 
 
In addition, a blood sample (~50mL; 3-4 table spoons) may  be obtained for: 
1. Hospital laboratory evaluations that may be obtained per standard of care, at standard 
of care time points during the hospital stay 
1. CBC 
2. BMP 
3. HbA1C Maybe obtained at some point during the course of the 6 day study if the 
patient did not have a value obtained within 3 month prior to the amputation) 
4. Pre-albumin (May be obtained at some point during the course of the 6 day study 
if the patient did not have a value obtained within 1 week prior to the amputation) 
 
2. Research laboratory evaluation 
1. One sample within 12 hours from the time of the amputation operation, if possible 
2. One sample within 12 hours prior to discharge from the hospital or by POD5, if 
possible 
3. Samples will be taken to the research laboratory to evaluate: 
1. Serum Insulin level 
2. Serum Thiol Level 
3. Serum L-Cysteine level 
4. Serum lipidomics 
5. Serum nicotine and cotinine levels 
6. Other essential plasma/serum proteins or biomarkers 
 
 
 
 
Contraindications to Measurement: 
- 
Patient refusal/inability to participate in measurement before or at time of data 
collection (a contraindication to anthropometric measurements does not exclude the 
patient from other measurements within the study protocol). 
- 
Severe anemia (Hematocrit < 22), that develops following enrollment in the study. 
 
 
Data Analysis: 
Anthropometric data will be analyzed to determine its effects on patient amputation stump healing 
score, qualitative peak perfusion, and/or quantitative peak perfusion. 
 
D. 
MRI Measurements 
 
 
Location of Procedure:  
- 
Center for Clinical Imaging Research 
 
Time of Data Collection:  

- 
Postoperative Day 4, If possible and/or equipment available and if the patient is still 
in-house. 
 
Contraindications to Measurement: 
- 
Patient refusal/inability to participate in measurement before or during data collection 
- 
Patient unable to lie supine for at least 30 minutes during measurement collection 
- 
Contraindication to MR scanning such as intracranial vascular clips, pacemaker or 
intraocular metal. 
- 
Patient is hemodynamically unstable, pregnant, are claustrophobic. 
 
MRI Procedural Steps: 
1.     The patient is asked to lie supine on a narrow bed in the MRI scanner. An MRI scanner 
is a large donut-shaped machine that is used by thousands of hospitals to make pictures of 
various parts of the body. The patient is given ear plugs or earphones to dampen the loud noise 
the scanner makes when taking pictures. The patient is also given a squeeze ball which can 
activate an alarm at the scanner operator’s console, so the patient can let the operator know to 
have a question or need assistance. 
2.       The patient is scanned under an existing non-contrast MRI protocol to obtain blood 
flow and tissue oxygenation pictures at rest. 
3.   Each study patient is carefully monitored by a physician, nurse practitioner, physician 
assistant or nurse for signs and symptoms of allergic reaction or intolerance to this non-invasive 
procedure until discharge. 
 
 
Visit 1  
Following patient discharge, amputation stumps will be evaluated within 20-50 days during a 
routine post-operative visit using the same anthropometric parameters (LAFA and TcPO2 will not 
be performed at this time point). 
 
Safety and Adverse Events  
 
Safety and Compliance Monitoring 
All study patients are inpatients at BJH in St. Louis Missouri and are cared for by appropriately 
trained nurses on the inpatient wards.  Vascular surgery Attending Physicians, Vascular Surgery 
Fellows, Surgical Residents, and a team of Nurse Practitioners oversee their overall care.  
Inpatient ward nurses routinely assess patients at least every 4 hours with vital signs, intake and 
output measurements, pain assessment, nutrition assessments, medication review and 
administration, etc.   
 
Medical Monitoring  
Medical monitoring of the study will be performed by the Principal Investigator.  The goal of 
monitoring this study is to enhance human subject protection and to monitor the quality of the 
clinical trial data by focusing investigator oversight on the most important aspects of study conduct 
and reporting.  The PI will provide regular oversight to ensure adequate protection of the rights, 
welfare, and safety of the human subjects and the quality of the clinical trial data. 

 
Definitions of Adverse Events 
 
An adverse event (AE) is defined as any untoward medical occurrence in a subject administered 
a pharmaceutical product or who has undergone study procedures and which does not 
necessarily have a causal relationship with this treatment.  An AE can therefore be any unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated with 
the use of the investigational product, whether or not related to the medicinal (investigational) 
product. 
 
All AEs will be recorded in the CRF from the time of consent through the 30 days post-operative 
visit. AEs will be followed to resolution or stabilization. 
An abnormality identified during a medical test (e.g., laboratory parameter, vital sign, physical 
exam) should be defined as an AE only if the abnormality meets one of the following criteria: 
● Induces clinical signs or symptoms 
● Requires active intervention 
● Requires interruption or discontinuation of study medication 
● The abnormality or investigational value is clinically significant in the opinion of the 
    investigator. 
 
An AE is considered “serious” if, in the view of the Investigator, it results in any of the following 
outcomes: 
• 
Results in death 
• 
Is life threatening (an AE is considered “life threatening” if, in the view of the investigator, 
its occurrence places the subject at immediate risk of death. It does not include an AE 
that, had it occurred in a more severe form, might have caused death) 
• 
Results in persistent or significant disability/incapacity or substantial disruption of the 
ability to conduct normal life functions 
• 
Results in congenital anomaly, or birth defect 
• 
Requires inpatient hospitalization or leads to prolongation of hospitalization 
(hospitalization for treatment/observation/examination caused by AE is to be considered 
as serious) 
• 
Other medically important events 
 
Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as important medical events that may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the subject or may require 
intervention to prevent one of the other outcomes listed in the definition above. These events, 
including those that may result in disability/incapacity, should also usually be considered serious. 
Examples of such events are intensive treatment in an emergency room or at home for allergic 
bronchospasm or blood dyscrasias or convulsions that do not result in hospitalization. 
 
Events related to the medicinal products administered to the subject as part of the study (e.g., 
study drug, comparator, background therapy) that may require expedited reporting, but are not 
limited to: 
• 
Overdose of the medicinal product(s) 
• 
Inadvertent or accidental exposure to the medicinal product(s) 
• 
Medication error involving the medicinal product(s)  
 

All AEs and events related to the medicinal product administered to the subject as part of the 
study will be recorded in the CRF from the time of consent through the 30 days post-operative 
visit.  AEs should be followed to resolution or stabilization. 
Classification of Events 
 
AEs are classified as serious or non-serious; expected or unexpected; and study-related, possibly 
study-related, or not study-related. 
Relationship 
 
Defining Relationship 
Adverse events that fall under either "Possible" or "Probable" should be defined as "AEs whose 
relationship to the study drugs could not be ruled out." Relationship to study drug will be assessed 
using the following criteria: 
 
Not Related           A clinical event, including laboratory test abnormality, with a 
                              temporal relationship to drug administration, which makes a causal 
                              relationship improbable, and/or in which other drugs, chemicals or 
                              underlying disease provide plausible explanations.       
 
Possible                 A clinical event, including laboratory test abnormality, with a 
                               reasonable time sequence to administration of the drug, but which 
                               could also be explained by concurrent disease or other drugs or 
                               chemicals. 
 
Probable                 A clinical event, including laboratory test abnormality, with a 
                               reasonable time sequence to administration of the drug, unlikely to 
                               be attributed to concurrent disease or other drugs or chemicals, and 
                               which follows a clinically reasonable response on re- administration 
                               (re-challenge) or withdrawal (de-challenge). 
Severity 
 
Defining Severity 
Grade 1 - Mild AE: Asymptomatic or mild symptoms, clinical or diagnostic observations noted; 
intervention not indicated.                        
 
Grade 2 - Moderate AE: Local or noninvasive intervention indicated. 
 
Grade 3 - Severe AE: Medically significant but not immediately life threatening hospitalization or 
prolonged hospitalization 
 
Grade 4 - Life-threatening: Life threatening consequences, urgent intervention indicated or 
disabling AE 
 
Grade 5 – Death: Death related to AE 
Expectedness 
 

All AEs that are previously unobserved or undocumented are referred to as “unexpected,” in that 
their nature and severity are not consistent with information provided in the relevant product 
information (e.g., approved professional package insert or product label). Determination of 
expectedness is made by the Investigator on a case-by-case basis. 
Data Collection Procedures for Adverse Events 
 
All adverse events must be documented in the subject’s medical record and/or Case Report Form 
(CRF). In order to prevent bias collection of AEs, subjects should not be questioned regarding 
specific events that might be anticipated while on the study.  AEs should be spontaneously 
reported or elicited from a subject using open-ended questioning during examination or 
evaluation.   
 
The AE CRF will include the start date (and time if applicable; e.g. It may be important to time the 
AE, especially with infusion reactions), a detailed description of the event, any treatment for the 
AE (e.g., no treatment needed, further testing to diagnosis event, hospitalization, dose reduction, 
holding of study intervention), Investigators assessment of the AE (serious or not serious, 
expected or unexpected, related or unrelated) and the date the AE resolved.  If an ongoing AE 
worsens or improves in its severity or its relationship to the study drug changes, documentation 
should be collected as above. 
 
Reporting Procedures 
 
Unanticipated problems and unexpected adverse drug events are defined below and will be 
reported to the local IRB according to local policy. 
 
An Unanticipated problem involving risks to participants or others: 
1. Are unexpected (in terms of nature, severity, or frequency) given (a) the research 
procedures that are described in the protocol-related documents, such as the IRB-
approved research protocol and informed consent document; and (b) the characteristics 
of the subject population being studied. 
2. Are related or possibly related to participation in the research. 
3. Suggest that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized. 
 
An unexpected adverse drug event:  
1. Any adverse drug experience (associated with the use of the drug), the frequency, 
specificity, or severity of which is not consistent with the current investigator brochure or 
package insert; or 
2. If an investigator brochure or package insert is not required or available, the specificity or 
severity of which is not consistent with the risk information provided to the participants and 
the IRB 
Adverse Event Reporting Period 
 
Per local IRB policy an individual adverse event that meets the definition of an anticipated problem 
involving risk to participants or others or an unexpected adverse drug event will be reported to 
the IRB within 10 working days.  If an unexpected adverse drug event results in a death the event 

will be reported to the IRB within 1 working day.  Individual adverse events that do not meet the 
definition of an unanticipated problem involving risks to participants will be reported to the IRB at 
the time of continuing review (annual renewal). 
Post-study Adverse Event 
 
All AEs will be recorded in the CRF from the time of consent through the 30 days post-operative 
visit however all AEs will be followed to resolution or stabilization. 
Study Outcome Measurements and Ascertainment 
As described previously, study subjects will undergo evaluations using LAFA, TcP02, and 
anthropometric measurements.    
 
Statistical Plan  
 
 Sample Size Determination and Power 
The purpose of this study is to obtain sufficient preliminary data to determine the sample size 
necessary for a future large definitive clinical trial. For this pilot study, we plan to enroll 25 patients 
in each group, allowing for a dropout rate of 10% per group. 
 
We emphasize that effect size (the expected difference in primary outcome between the treatment 
and control groups) should not be determined by the pilot study. Rather it is determined by the 
minimum clinically important difference. However, the effect size from the pilot give us some ideas 
about possible achievable difference. 
 Interim Monitoring and Early Stopping 
An interim analysis will be conducted once >30 patients are enrolled in the study. Analysis will 
focus on determining differences between NAC and control group. Interim analysis will help 
determine early differences between the study groups and safety profile of study intervention. The 
investigators may end the study early depending on study findings, safety profile of the data, 
and/or if data is adequate for a peer-reviewed publication. 
 Analysis Plan 
Data analysis include (1) the partition of variation of outcome measurements into within and 
between patient components to obtain standard deviation of measurements, intra-class 
correlation of the measurements, (2) use of appropriate regression model (GEE or mixed effect 
regression) to compare the outcome measurements between two groups, while accounting for 
the intra-class correlation. Interpretation of analysis should be made within the context of a pilot 
study where we have a pre-specified hypothesis but do not have power analysis for testing the 
hypothesis. 
 
 Statistical Methods  
One of the main study outcomes (and in the future large study) is the stump perfusion 
assessment, which is a continuous variable measured three times (D0, D3, and D5) after 

treatment. Based on this longitudinal repeated measurement study design, the preliminary data 
needed for designing future study include: (1) variance of single measurement, (2) covariance 
(correlation) among the repeated measurements over time within an individual, (3) level of 
outcome measurements in patients with and without the treatment.  
 
 Missing Outcome Data 
Not applicable 
 Unblinding Procedures  
The BJH Investigational Pharmacy will maintain a record of each patient’s medical record number 
and to which arm of the study they were assigned.  No member of the vascular surgery 
investigational team will have access to this information. This will serve to maintain blinding and 
reduce any unwanted during the trial and subsequent analysis of collected data.  Un-blinding of 
patient data will occur during the interim analysis, and at the end of the study. For un-blinding the 
pharmacy will then un-blind the study to the investigators such that appropriate conclusions can 
be made regarding the efficacy of the investigational agent.  
 
 
Data Handling and Record Keeping  
 
Confidentiality and Security 
All patient data and demographic information will be analyzed on computers on the Washington 
University in St. Louis (WUSTL) network.  This network is only accessible through appropriately 
credentialed employees, physicians, and Washington University of St. Louis medical students.  
Additionally, data is stored on the WUSTL network drive, with separate encryption levels, only 
accessible by users granted permissions by the appropriate administrator.  This prevents 
unauthorized users, i.e. those not immediately involved in specific projects, from gaining access 
to patient sensitive information. 
 
Samples and/or data from this research may be shared with other researchers for future projects.  
All requests, inclusive of proof of review and approval by the Institutional Review Board as 
applicable, from potential research collaborators will be reviewed on a case by case basis, in 
writing, by the Principal Investigator(s) prior to the release of samples/data. The data and/or 
samples approved for release will then be provided to other investigators and will be de-identified 
(coded).  Only the primary NAC study team members have access to the password-protected link 
to protect patient confidentiality.   
 
Training  
All individuals responsible for handling of patient information and/or the consenting process for 
this clinical trial have been approved and received appropriate training in line with the standards 
set for by the Washington University in St. Louis Office of the Vice Chancellor for Research.  
These individuals may include clinical trial nurse coordinators, clinical nurses, clinical fellows, 
research fellows, and vascular surgery attendings. 
 

Case Report Forms and Source Documents 
N/A 
Records Retention 
Records will be maintained for at least 7 years following the close of this study. 
Study Monitoring 
 
Study Monitoring Plan  
Monitoring will be used as a quality control tool to be sure that the study is being conducted as 
planned and as approved by the institutional IRB. Monitoring activities will include regular 
communication between the PI and study staff; review of the study processes, procedures, and 
records; assurance of protocol compliance and verification of the accuracy of data collected by 
the study team.  All data collected for the study will have a reliable source document to verify the 
source of the data.  Review of the data for each enrolled subject will be performed on an ongoing 
basis by the study team (including participant recruitment, accrual and retention, review of 
documentation of proper informed consent, source document verification, adverse events 
identification and reporting activities).  Conclusions of the ongoing monitoring activities will be 
reported to the PI. Ongoing monitoring findings will be evaluated to determine whether additional 
actions (e.g., training of clinical investigator and site staff, clarification of protocol requirements) 
are necessary to ensure human subject protection and data quality. 
 
Any incidence of protocol noncompliance and all unanticipated problems will be reported to the 
IRB in accordance with local policy.  The study Principal Investigator will perform continuous 
monitoring of participant safety based on regular review of adverse events captured in the clinical 
trial.  
 
The PI will ensure monitoring of the conduct and progress of the study that ensures:  
1) important information that may affect the safety or welfare of participants comes to light and is 
acted upon as quickly as possible, and 2) the validity and integrity of the data.  The PI will 
determine based on ongoing safety review whether the study should continue as planned or 
should be modified/amended or stopped for safety concerns. 
 
Study Administration 
 
Organization and Participating Centers 
The study will be performed at the Washington University School of Medicine-affiliated Barnes 
Jewish Hospital. 
Funding Source and Conflicts of Interest 
The study is funded by a Pilot and Feasibility Grant from the Diabetes Research Center.  This is 
an NIH/NIDDK sponsored grant (P30 DK020579) 

Committees 
N/A 
Subject Stipends or Payments  
No subject stipends or payments will be offered or available for this clinical study 
 
 Study Timetable 
 
 
Publication Plan  
 
We plan to make clinical trial findings public and aim to publish the study findings in a peer-
reviewed scientific journal. 
 
 
 Attachments  
 
 Tables  
N/A 
 Informed consent documents 
See attachment 
 Patient education brochures 
N/A 
Special procedures protocols  
N/A 
 Questionnaires or surveys 
N/A 
 

 
References 
 
1. 
Biancari, F., Meta-analysis of the prevalence, incidence and natural history of critical limb 
ischemia. J Cardiovasc Surg (Torino), 2013. 54(6): p. 663-9. 
2. 
Zayed, M., F. Bech, and T. Hernandez-Boussard, National review of factors influencing 
disparities and types of major lower extremity amputations. Ann Vasc Surg, 2014. 28(5): 
p. 1157-65. 
3. 
Dillingham, T.R., L.E. Pezzin, and A.D. Shore, Reamputation, mortality, and health care 
costs among persons with dysvascular lower-limb amputations. Arch Phys Med Rehabil, 
2005. 86(3): p. 480-6. 
4. 
Samuni, Y., et al., The chemistry and biological activities of N-acetylcysteine. Biochim 
Biophys Acta, 2013. 1830(8): p. 4117-29. 
5. 
Zafarullah, M., et al., Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci, 
2003. 60(1): p. 6-20. 
6. 
Prescott, L.F., et al., Intravenous N-acetylcysteine: still the treatment of choice for 
paracetamol poisoning. Br Med J, 1980. 280(6206): p. 46-7. 
7. 
Brok, J., N. Buckley, and C. Gluud, Interventions for paracetamol (acetaminophen) 
overdose. Cochrane Database Syst Rev, 2006(2): p. CD003328. 
8. 
Ardissino, D., et al., Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the 
long-term treatment of unstable angina pectoris. J Am Coll Cardiol, 1997. 29(5): p. 941-7. 
9. 
Dekhuijzen, P.N., Antioxidant properties of N-acetylcysteine: their relevance in relation to 
chronic obstructive pulmonary disease. Eur Respir J, 2004. 23(4): p. 629-36. 
10. 
Liu, R., et al., N-acetylcysteine for the prevention of contrast-induced nephropathy. A 
systematic review and meta-analysis. J Gen Intern Med, 2005. 20(2): p. 193-200. 
11. 
Blouet, C., et al., Dietary cysteine alleviates sucrose-induced oxidative stress and insulin 
resistance. Free Radic Biol Med, 2007. 42(7): p. 1089-97. 
12. 
Diniz, Y.S., et al., Effects of N-acetylcysteine on sucrose-rich diet-induced 
hyperglycaemia, dyslipidemia and oxidative stress in rats. Eur J Pharmacol, 2006. 543(1-
3): p. 151-7. 
13. 
Gregg, E.W., et al., Changes in diabetes-related complications in the United States, 1990-
2010. N Engl J Med, 2014. 370(16): p. 1514-23. 
14. 
Kolluru, G.K., S.C. Bir, and C.G. Kevil, Endothelial dysfunction and diabetes: effects on 
angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med, 2012. 2012: p. 
918267. 
15. 
Hoffstad, O., et al., Diabetes, lower-extremity amputation, and death. Diabetes Care, 
2015. 38(10): p. 1852-7. 
16. 
Dodd, S., et al., N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. 
Expert Opin Biol Ther, 2008. 8(12): p. 1955-62. 
17. 
Wang, T., et al., N-Acetylcysteine and allopurinol up-regulated the Jak/STAT3 and 
PI3K/Akt pathways via adiponectin and attenuated myocardial postischemic injury in 
diabetes. Free Radic Biol Med, 2013. 63: p. 291-303. 
18. 
Lasram, M.M., et al., A review on the possible molecular mechanism of action of N-
acetylcysteine against insulin resistance and type-2 diabetes development. Clin Biochem, 
2015. 48(16-17): p. 1200-8. 
19. 
Franceschini, G., et al., Dose-related increase of HDL-cholesterol levels after N-
acetylcysteine in man. Pharmacol Res, 1993. 28(3): p. 213-8. 
20. 
Manna, P. and S.K. Jain, Hydrogen sulfide and L-cysteine increase phosphatidylinositol 
3,4,5-trisphosphate (PIP3) and glucose utilization by inhibiting phosphatase and tensin 

homolog (PTEN) protein and activating phosphoinositide 3-kinase (PI3K)/serine/threonine 
protein kinase (AKT)/protein kinase Czeta/lambda (PKCzeta/lambda) in 3T3l1 adipocytes. 
J Biol Chem, 2011. 286(46): p. 39848-59. 
21. 
Thiruvoipati, T., C.E. Kielhorn, and E.J. Armstrong, Peripheral artery disease in patients 
with diabetes: Epidemiology, mechanisms, and outcomes. World J Diabetes, 2015. 6(7): 
p. 961-9. 
22. 
Marenzi, G., et al., N-acetylcysteine and contrast-induced nephropathy in primary 
angioplasty. N Engl J Med, 2006. 354(26): p. 2773-82. 
23. 
Kapp, M.B., Ethical and legal issues in research involving human subjects: do you want a 
piece of me? J Clin Pathol, 2006. 59(4): p. 335-9. 
24. 
Holdiness, M.R., Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet, 
1991. 20(2): p. 123-34. 
 
 
 

 
STATISTICAL ANALYSIS PLAN 
 
 
 
Protocol Title:  N-Acetyl-Cysteine for Healing of 
Amputation Stumps in the Setting of Diabetes 
 
 
NCT03253328 
 
 
Protocol Version 11.0 
Date: March 26, 2020 
 
 

 
Statistical Plan  
 
 Sample Size Determination and Power 
The purpose of this study is to obtain sufficient preliminary data to determine the sample size 
necessary for a future large definitive clinical trial. For this pilot study, we plan to enroll 25 patients 
in each group, allowing for a dropout rate of 10% per group. 
 
We emphasize that effect size (the expected difference in primary outcome between the treatment 
and control groups) should not be determined by the pilot study. Rather it is determined by the 
minimum clinically important difference. However, the effect size from the pilot give us some ideas 
about possible achievable difference. 
 Interim Monitoring and Early Stopping 
An interim analysis will be conducted once >30 patients are enrolled in the study. Analysis will 
focus on determining differences between NAC and control group. Interim analysis will help 
determine early differences between the study groups and safety profile of study intervention. The 
investigators may end the study early depending on study findings, safety profile of the data, 
and/or if data is adequate for a peer-reviewed publication. 
 Analysis Plan 
Data analysis include (1) the partition of variation of outcome measurements into within and 
between patient components to obtain standard deviation of measurements, intra-class 
correlation of the measurements, (2) use of appropriate regression model (GEE or mixed effect 
regression) to compare the outcome measurements between two groups, while accounting for 
the intra-class correlation. Interpretation of analysis should be made within the context of a pilot 
study where we have a pre-specified hypothesis but do not have power analysis for testing the 
hypothesis. 
 
 Statistical Methods  
One of the main study outcomes (and in the future large study) is the stump perfusion 
assessment, which is a continuous variable measured three times (D0, D3, and D5) after 
treatment. Based on this longitudinal repeated measurement study design, the preliminary data 
needed for designing future study include: (1) variance of single measurement, (2) covariance 
(correlation) among the repeated measurements over time within an individual, (3) level of 
outcome measurements in patients with and without the treatment.  
 
 Missing Outcome Data 
Not applicable 

 Unblinding Procedures  
The BJH Investigational Pharmacy will maintain a record of each patient’s medical record number 
and to which arm of the study they were assigned.  No member of the vascular surgery 
investigational team will have access to this information. This will serve to maintain blinding and 
reduce any unwanted during the trial and subsequent analysis of collected data.  Un-blinding of 
patient data will occur during the interim analysis, and at the end of the study. For un-blinding the 
pharmacy will then un-blind the study to the investigators such that appropriate conclusions can 
be made regarding the efficacy of the investigational agent.  
 
 

 
CONSENT DOCUMENT 
 
 
 
Protocol Title:  N-Acetyl-Cysteine for Healing of 
Amputation Stumps in the Setting of Diabetes 
 
 
NCT03253328 
 
 
Protocol Version 11.0 
Date: March 26, 2020 
 
 
 

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
INFORMED CONSENT DOCUMENT 
 
 
Project Title: 
N-Acetyl-Cysteine for Healing of Amputation Stumps in the Setting of Diabetes 
 
 
Principal Investigator: 
Mohamed Zayed, M.D. Ph.D. 
 
Research Team Contact: 
Ashley Burgess, RN, BSN (314) 362-6257 
                            Julie Wilson, RN  (314) 747-7828 
                            Vanetta Worthy, BS (314) 273-0872 
 
If you are the legally authorized representative of a person who is being invited to participate in this 
study, the word “you” in this document refers to the person you represent.  As the legally authorized 
representative, you will be asked to read and sign this document to give permission for the person you 
represent to participate in this research study.   
 
This consent form describes the research study and helps you decide if you want to participate.  It 
provides important information about what you will be asked to do during the study, about the risks and 
benefits of the study, and about your rights and responsibilities as a research participant. By signing this 
form you are agreeing to participate in this study. 
• 
You should read and understand the information in this document including the procedures, 
risks and potential benefits.  
• 
If you have questions about anything in this form, you should ask the research team for more 
information before you agree to participate.   
• 
You may also wish to talk to your family or friends about your participation in this study. 
• 
Do not agree to participate in this study unless the research team has answered your 
questions and you decide that you want to be part of this study.  
 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
This is a research study.  We invite you to participate in this research study because you are scheduled to 
undergo elective above-knee or below-knee amputation due to critical limb ischemia (CLI), with and 
without diabetes mellitus.    
 
Diabetes is a significant factor for peripheral arterial disease (PAD) and critical limb ischemia (CLI).  
PAD is caused by atherosclerosis, the hardening and narrowing of the arteries, over time due to the 
buildup of fatty deposits called plaque.  Critical limb ischemia (CLI) is a severe form of PAD, and is a 
chronic condition that results in severe pain in the feet or toes, even while resting. Complications of poor 
circulation can include sores and wounds that won't heal in the legs and feet.  
 
The purpose of this research study is to evaluate the effectiveness and safety of using a drug called, N-

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
Acetyl-Cysteine (NAC) in the setting of PAD as a tissue augmenting agent in patients undergoing lower 
limb amputation with and without diabetes mellitus. NAC is approved by the U.S. Food and Drug 
Administration for acetaminophen (Tylenol) overdose, carbon monoxide poisoning, and multiple other 
uses including as a medication to thin mucous in respiratory conditions such as cystic fibrosis or 
bronchitis.  NAC is considered investigational for its use in this study which means that it has not been 
approved by the U.S. Food and Drug Administration.  This is a Pilot Clinical Trial study designed to 
establish if there is any benefit in using NAC for patients undergoing lower limb amputation with 
respect to improving stump circulation and perfusion (increase blood flow to the extremity), improving 
wound healing and serum lipidomics.  Lipidomics is the study of the variety of fatty molecules in the 
body, their cellular and extracellular functions and interactions, and the diseases to which they 
contribute.  We are evaluating NAC because prior research studies have shown it to be effective in 
improving wound healing. 
 
This study will only be conducted at Washington University/Barnes-Jewish Hospital.   
 
 
WHAT WILL HAPPEN DURING THIS STUDY? 
In this study, you will have your above-knee or below-knee amputation surgical procedure according to 
standard care.  This study will not change your surgery or how it is performed.  Research procedures 
will occur during your recovery period after surgery.  
 
We will recruit at least 50 participants:  25 patients will receive the study drug, NAC, at a standard, 
commonly used dose of 1200mg intravenously (IV) twice a day for 6 consecutive days after surgery 
(treatment group).  The other 25 participants will receive placebo saline intravenous (IV) infusion twice 
a day for 6 consecutive days after surgery (control group).  You will be randomly chosen, like the flip of 
a coin, to one of these two groups.  Neither you nor the study doctor will know to which group you will 
be assigned. 
 
After informed consent is obtained, a baseline clinical evaluation will be performed including lower 
extremity anthropometric evaluation, medical history and vital signs documentation.  Anthropometric 
evaluation is the measurement of the size and proportion of your amputated stump. 
 
As part of your standard care you will also have blood draws to assess laboratory values for a complete 
blood count (CBC) and a basic metabolic panel.  As part of standard of care, you will have an HbA1C 
drawn if it has not been checked within 3 months and a pre-albumin level if it has not been checked 
within 1 week prior to amputation. These tests are done as standard care and will be done whether you 
participate in this study or not. 
 
In addition, for research purposes, a sample of blood, approximately 3-4 teaspoons, will be taken within 
12 hours of the amputation operation, if possible and another sample will be taken within 12 hours prior 
to discharge from the hospital, or by Day 5, if possible.  A portion of your blood sample will be used to 
obtain laboratory evaluations of your serum insulin level, serum thiol level, serum L-cysteine levels, 

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
serum lipidomics, serum nicotine and cotinine levels, and other essential plasma serum proteins or 
biomarkers.  
 
 
Non-invasive Laser Assisted Fluorescence Angiography (LAFA) 
We will assess blood circulation and wound healing in your stump by using a special angiogram. A dye, 
ICG, will be injected through your IV that will allow us to see blood flow and allow us to take images. 
You will be asked to lie still for about 10 minutes. 
 
This imaging will occur at three (3) time points: in the operating room after your amputation, at your 
bedside on Day 3, and on Day 5 at your bedside if you are still in the hospital. If we are unable to obtain 
the image in the operating room, your study participation will end however you will continue to receive 
your standard medical care.  
 
 
Measurement of Transcutaneous Oxygen Pressure (TcPO2) 
This procedure assesses the amount of oxygen that reaches your skin through blood circulation. We will 
place three (3) adhesive sensors on your stump and one (1) adhesive sensor on your chest.  Each sensor 
contains an electrode that can sense oxygen flow. This procedure will take about 15 minutes. 
 
This procedure will be performed at three (3) time points:  obtained prior to the operation, if possible, at 
your bedside on Day 3 if possible, and on Day 5 if possible, at your bedside if you are still in the 
hospital. 
 
Throughout your hospitalization, we will collect information about your medical condition such as vital 
signs, changes in health (adverse events), medication use and amputated stump measurement 
information. 
 
Following discharge, your amputated stump will be evaluated within 20-30 days during a routine 
postoperative visit.  At this time we will collect information including records describing stump healing 
or care, any changes in your health, your temperature, blood pressure, heart rate, breathing rate and 
blood oxygen level as part of the research study. 
 
 
Will you save my samples or research data to use in future research studies?  
As part of this study, we are obtaining blood sample(s) and/or data from you. We would like to use the 
blood sample(s) and/or data for studies going on right now as well as studies that are conducted in the 
future.  These studies may provide additional information that will be helpful in understanding 
peripheral arterial disease (PAD) and critical limb ischemia (CLI), or other diseases or conditions, 
including research to develop investigational tests, treatments, drugs or devices that are not yet approved 

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
by the U.S. Food and Drug Administration.  It is unlikely that what we learn from these studies will have 
a direct benefit to you.  There are no plans to provide financial compensation to you should this occur.  
By allowing us to use your blood sample(s) and/or data you give up any property rights you may have in 
the blood sample(s) and/or data. 
We will share your blood sample(s) and/or data with other researchers. They may be doing research in 
areas similar to this research or in other unrelated areas.  These researchers may be at Washington 
University, at other research centers and institutions, or industry sponsors of research.  We may also 
share your research data with large data repositories (a repository is a database of information) for broad 
sharing with the research community.  If your individual research data is placed in one of these 
repositories only qualified researchers, who have received prior approval from individuals that monitor 
the use of the data, will be able to look at your information.   
If you change your mind and do not want us to store and use your blood sample(s) and/or data for future 
research you should contact the research team member identified at the top of this document.  The blood 
sample(s) and/or data will no longer be used for research purposes. However, if some research with your 
blood sample(s) and/or data has already been completed, the information from that research may still be 
used. Also, if the blood sample(s) and/or data has been shared with other researchers it might not be 
possible to withdraw the blood sample(s) and/or data to the extent it has been shared. 
Please place your initials in the blank next to Yes or No for each of the questions below: 
 
My blood sample(s) and/or data may be stored and used for future research as described above. 
 
_____ Yes 
_____ No 
Initials  
Initials 
 
My blood sample(s) and/or data may be shared with other researchers and used by these 
researchers for the future research as described above. 
 
_____ Yes  
_____ No 
Initials  
Initials 
 
In addition, you may be randomly chosen, like the flip of a coin, to have a magnetic resonance image 
performed on your stump to check blood flow and oxygen (for perfusion assessments).  Neither the PI 
nor the study staff will know if you are from the group who will receive NAC or placebo.  This MR 
imaging will take approximately 45 – 60  minutes and you will be asked to lie down on a narrow bed in 
the MRI scanner.  An MRI scanner is a large donut-shaped machine that is used by thousands of 
hospitals to make pictures of various parts of the body.  The MRI scanner does not expose you to 
ionizing radiation (x-rays).  You will be given ear plugs to dampen the loud noise the scanner makes 
when taking pictures.  You will be given a squeeze ball which can activate an alarm at the scanner 
operator’s console so you can let the operator know you have a question or need assistance. 
 

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
 
HOW MANY PEOPLE WILL PARTICIPATE? 
At least 50 people will take part in this study conducted by investigators at Washington University.   
 
 
HOW LONG WILL I BE IN THIS STUDY? 
If you agree to take part in this study, your participation will last for approximately 30 days following 
your surgery. 
 
 
WHAT ARE THE RISKS OF THIS STUDY? 
You may experience one or more of the risks indicated below from being in this study.  In addition to 
these, there may be other unknown risks, or risks that we did not anticipate, associated with being in this 
study.  
 
Some risks described in this consent document, if severe, may cause death. 
Risks of N-Acetyl-Cysteine (NAC) 
 
Rare   
Life Threatening 
• Anaphylaxis (severe allergic) reaction to NAC 
Serious 
• Wheezing 
• Tightness in the chest 
• Difficulty breathing 
Mild 
• Rash 
• Urticaria (hives) 
• Pruritus (itching) reaction 
• Infection at the site of the injection 
• Venous thrombosis (clot) 
• Phlebitis (inflammation of a vein) at the site of the IV 
• Chance leakage of saline fluid at the site of the injection 
 
Concurrent use of NAC and nitroglycerin may result in enhanced hypotension (low blood pressure) and 
nitroglycerin-induced headache.  If you are on nitroglycerin, notify your doctor if you feel light headed 
or weak as this may be a sign of low blood pressure.  Nitroglycerin is known to cause headaches but if 
your headache becomes worse notify your doctor.  Adjustments to your medications may need to be 
made. 

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
Risk of Saline Infusion 
Rare   
Mild 
• Infection at the site of the injection 
• Venous thrombosis (clot) 
• Phlebitis (inflammation of a vein) at the site of the IV 
• Chance leakage of saline fluid at the site of the injection 
Risk of Indocyanine Green (ICG) for Laser Assisted Fluorescence Angiography (LAFA) 
Rare   
Life Threatening 
• Anaphylaxis (severe allergic) reaction to ICG 
Serious 
• Difficulty breathing 
Mild 
• Urticarial (hives) reaction to ICG 
• Flushing 
• Itching 
 
Risks associated with the blood draw may include: 
Likely: 
Mild 
• Pain at the needle stick site 
Less Likely / Less Common 
Mild 
• The blood draw may cause bleeding or bruising. 
Rare 
Serious 
• Some people become dizzy or feel faint. 
• There is also a rare risk of infection 
 
 
Risks associated with MRI scan: 
 
MRI 
You may be uncomfortable inside the MRI scanner if you do not like ot be in closed spaces 
(“claustrophobia”).  During the procedure, you will be able to talk with the MRI staff through a speaker 
system.  You can tell them to stop the scan at any time. 
 
The MRI scanner produces a loud hammering noise, which has caused hearing loss in a very small 
number of patients.  You will be given earplugs to reduce this risk. 

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
 
There is a risk of burns that could be serious. 
 
If you have a device such as a pacemaker, bone hardware, or device placed in your uterus there may be 
additional risks.  We will review what device you have and inform you of these risks.  In general, these 
risks could be: 
• Heating or movement of the device 
• Device malfunction 
• Damage to the tissue that surrounds the device 
 
If you have a skin tattoo, including cosmetic tattoos (eye-liner, lip-liner) you could experience the 
following: 
• Irritation, swelling or heating in the area of the tattoo(s) 
• In rare instances a primary or secondary burn 
 
If you have a tattoo we will offer you a cold wet washcloth to put over the tattoo to reduce this risk. 
 
Breach of Confidentiality 
One risk of participating in this study is that confidential information about you may be accidentally 
disclosed.  We will use our best efforts to keep the information about you secure.  Please see the section 
in this consent form titled “How will you keep my information confidential?” for more information. 
 
WHAT ARE THE BENEFITS OF THIS STUDY? 
You may or may not benefit from being in this study.   
 
However, we hope that, in the future, other people might benefit from this study because information 
collected from this clinical trial may benefit a larger number of patients with critical limb ischemia 
(CLI) with and without diabetes who are at risk of poor amputation stump healing. 
 
WHAT OTHER TREATMENT OPTIONS ARE THERE? 
Before you decide whether or not to be in this study, your doctor will discuss the other options that are 
available to you.  You do not have to participate in this study.  If you choose not to participate, you will 
not receive NAC.  Your decision will not impact your standard care.   
 
WILL IT COST ME ANYTHING TO BE IN THIS STUDY? 
As part of this study you will receive tests and procedures that are similar to what you would receive 
during routine clinical care of your condition.  Your health plan/insurance company will be billed for 
some or all of these costs, and you will be responsible for any co-pays and deductibles that are normally 
required by your health plan/insurance.  Not all insurance plans cover the costs associated with being in 
a study. Even if they do, you may be responsible for more out-of-pocket expenses, such as co-pays and 

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
deductibles, when there are more tests and procedures or more expensive tests and procedures involved 
in the study than if you were to receive routine clinical care outside the study.   
 
If you wish to know whether there are more tests and procedures or more expensive tests and procedures 
in the study, you should ask your study doctor. 
 
If you wish to know whether your insurance will pay, you should contact them directly, or speak with 
the study team about obtaining a financial pre-certification prior to enrolling in the study. 
 
You will not have any costs associated with the MR imaging.  
 
WILL I BE PAID FOR PARTICIPATING? 
You will not be paid for being in this research study.   
 
 
WHO IS FUNDING THIS STUDY? 
 
The University and the research team are not receiving payment from other agencies, organizations, or 
companies to conduct this research study.  
 
 
WHAT IF I AM INJURED AS A RESULT OF THIS STUDY? 
Washington University investigators and staff will try to reduce, control, and treat any complications 
from this research. If you feel you are injured because of the study, please contact the investigator at 
(314) 362-5707 and/or the Human Research Protection Office at 1-(800)-438-0445.  
 
Decisions about whether payment for medical treatment for injuries relating to your participation in 
research will be made by Washington University.  If you need to seek medical care for a research-related 
injury, please notify the investigator as soon as possible.  
 
 
HOW WILL YOU KEEP MY INFORMATION CONFIDENTIAL? 
We will keep your participation in this research study confidential to the extent permitted by law.  
However, it is possible that other people such as those indicated below may become aware of your 
participation in this study and may inspect and copy records pertaining to this research.  Some of these 
records could contain information that personally identifies you.  
• 
Government representatives, (including the Office for Human Research Protections) to complete 
federal or state responsibilities 
• 
The U.S. Food and Drug Administration 

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
• 
Your primary care physician if a medical condition that needs urgent attention is discovered 
• 
Hospital or University representatives, to complete Hospital or University responsibilities 
• 
The last four digits of your social security number may be used in hospital or University systems 
to track billing information for research procedures 
• 
Information about your participation in this study may be documented in your health care records 
and be available to your health care providers who are not part of the research team.  
• 
Washington University’s Institutional Review Board (a committee that oversees the conduct of 
research involving human participants) and the Human Research Protection Office. The 
Institutional Review Board has reviewed and approved this study.  
 
To help protect your confidentiality, we will only collect data as it pertains to this study.  You will be 
assigned a study code and your data will be collected using the study code.  All of your study records 
will be maintained by the study staff, kept in a locked file within a locked office, and access will be 
limited to only those on the study team.  We will maintain an electronic enrollment log that will contain 
identifiable information along with your specific study code.  This electronic enrollment log will be 
stored behind a firewall on a Washington University server.  All computers are password protected and 
only those on the research team will have access to this electronic data.  Blood samples collected as part 
of the research will be labeled with your study code and will be maintained in a locked -80 degree 
celsius freezer contained in the study investigator’s laboratory.  If we write a report or article about this 
study or share the study data set with others, we will do so in such a way that you cannot be directly 
identified. 
This consent form or similar documentation that you are participating in a research study will be 
included in your health care record.  Anyone with access to your health care record, including your 
health insurance company will be able to see that you are participating in a research study. 
 
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. 
Law. This Web site will not include information that can identify you. At most, the Web site will 
include a summary of the results. You can search this Web site at any time. 
 
 
Are there additional protections for my health information? 
Protected Health Information (PHI) is health information that identifies you. PHI is protected by federal 
law under HIPAA (the Health Insurance Portability and Accountability Act). To take part in this 
research, you must give the research team permission to use and disclose (share) your PHI for the study 
as explained in this consent form.  The research team will follow state and federal laws and may share 
your health information with the agencies and people listed under the previous section titled, “How will 
you keep my information confidential?” 
 
Once your health information is shared with someone outside of the research team, it may no longer be 
protected by HIPAA.   
 
The research team will only use and share your information as talked about in this form or as permitted 

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
or required by law.  When possible, the research team will make sure information cannot be linked to 
you (de-identified).  Once information is de-identified, it may be used and shared for other purposes not 
discussed in this consent form. If you have questions or concerns about your privacy and the use of your 
PHI, please contact the University’s Privacy Officer at 866-747-4975.  
 
Although you will not be allowed to see the study information, you may be given access to your health 
care records by contacting your health care provider.  
 
If you decide not to sign this form, it will not affect 
• your treatment or the care given by your health provider. 
• your insurance payment or enrollment in any health plans.   
• any benefits to which you are entitled. 
However, it will not be possible for you to take part in the study. 
If you sign this form: 
• You authorize the use of your PHI for this research 
• This authorization does not expire. 
• You may later change your mind and not let the research team use or share your information 
(you may revoke your authorization).  
• To revoke your authorization, complete the withdrawal letter, found in the Participant section of 
the Human Research Protection Office website at 
https://hrpo.wustl.edu/participants/withdrawing-from-a-study/ or you may request that the 
investigator send you a copy of the letter.     
 
 
o  If you revoke your authorization: 
 The research team may only use and share information already collected for the 
study. 
 Your information may still be used and shared as necessary to maintain the 
integrity of the research, for example, to account for a participant’s withdrawal 
from the research study or for safety reasons. 
 You will not be allowed to continue to participate in the study. 
 
 
IS BEING IN THIS STUDY VOLUNTARY? 
Taking part in this research study is completely voluntary.  You may choose not to take part at all.  If 
you decide to be in this study, you may stop participating at any time. Any data that was collected as 
part of your participation in the study will remain as part of the study records and cannot be removed.   
 
If you decide not to be in this study, or if you stop participating at any time, you won’t be penalized or 
lose any benefits for which you otherwise qualify.   
 
What if I decide to withdraw from the study? 
You may withdraw by telling the study team you are no longer interested in participating in the study or 

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
you may send in a withdrawal letter. A sample withdrawal letter can be found at 
https://hrpo.wustl.edu/participants/withdrawing-from-a-study/under Withdrawing from a Research 
Study. 
 
Will I receive new information about the study while participating? 
If we obtain any new information during this study that might affect your willingness to continue 
participating in the study, we’ll promptly provide you with that information. 
 
Can someone else end my participation in this study? 
Under certain circumstances, the investigator might decide to end your participation in this research 
study earlier than planned.  This might happen for no reason, or if you are found in the judgement of the 
investigation team to be developing a side effect or adverse reaction to the medication.  The study may 
also be terminated if funding for the research study has ended. 
 
WHAT IF I HAVE QUESTIONS? 
We encourage you to ask questions.  If you have any questions about the research study itself, please 
contact: Dr. Zayed at (314) 362-5648 or a study team member at (314) 362-5707.  If you experience 
a research-related injury, please contact: Dr. Zayed at (314) 362-5648 or a study team member at 
(314) 362-5707. 
 
If you have questions, concerns, or complaints about your rights as a research participant, please contact 
the Human Research Protection Office at 660 South Euclid Avenue, Campus Box 8089, St. Louis, MO  
63110, 1-(800)-438-0445, or email hrpo@wustl.edu. General information about being a research 
participant can be found on the Human Research Protection Office web site, hrpo.wustl.edu. To offer 
input about your experiences as a research participant or to speak to someone other than the research 
staff, call the Human Research Protection Office at the number above. 
 
 
 
This consent form is not a contract. It is a written explanation of what will happen during the study if 
you decide to participate. You are not waiving any legal rights by agreeing to participate in this study. 
As a participant you have rights and responsibilities as described in this document and including: 
• To be given enough time before signing below to weigh the risks and potential benefits and 
decide if you want to participate without any pressure from the research team or others. 
• To understand all of the information included in the document, have your questions answered, 
and receive an explanation of anything you do not understand. 
• To follow the procedures described in this document and the instructions of the research team to 
the best of your ability unless you choose to stop your participation in the research study. 
• To give the research team accurate and complete information. 
• To tell the research team promptly about any problems you have related to your participation, or 

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
if you are unable to continue and wish to stop participating in the research study. 
Your signature indicates that this research study has been explained to you, that your questions have 
been answered, and that you agree to take part in this study.  You will receive a signed and dated copy 
of this form. 
 
Do not sign this form if today’s date is after $STAMP_EXP_DT. 
 
__________________________________________ 
_______________________________ 
(Signature of Participant) 
 
 
 
 
(Date) 
 
____________________________________________ 
(Participant's name – printed) 
Legally Authorized Representative’s Name and Relationship to Participant: 
 
Do not sign this form if today’s date is after $STAMP_EXP_DT. 
 
 
______________________________ 
(Participant’s name – printed) 
 
 
__________________________________________ 
_______________________________ 
(Signature of Legally Authorized Representative) 
 
(Date) 
 
 
__________________________________________ 
_______________________________ 
(Name of Legally Authorized Representative - printed) 
(Relationship to Participant – printed) 
 
 
Who should sign as the Legally Authorized Representative (LAR)? 
If the participant has a legal guardian or attorney-in-fact this individual must sign as the LAR.    
 
If there is no legal guardian or attorney-in-fact the individuals listed below may sign in order of priority.  
 
(1) Spouse unless the participant has no spouse, or is separated, or the spouse is physically or mentally incapable 
of giving consent, or the spouse's whereabouts is unknown or the spouse is overseas;  
(2) Adult child;  
(3) Parent;  
(4) Brother or sister;  

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT 
 
 
(5) Relative by blood or marriage.  
 
 
Statement of Person Who Obtained Consent 
 
The information in this document has been discussed with the participant or, where appropriate, with the 
participant’s legally authorized representative.  The participant has indicated that they understand the 
risks, benefits, and procedures involved with participation in this research study. 
 
 
__________________________________________ 
_______________________________ 
(Signature of Person who Obtained Consent) 
 
(Date) 
 
 
___________________________________________ 
(Name of Person who Obtained Consent - printed)

 
FOR IRB USE ONLY 
$STAMP_IRB_ID 
$STAMP_APPRV_DT 
$STAMP_REL_DT 
$STAMP_EXP_DT